JPRN-UMIN000043392招募中未知
COmparing New strategy Targeting aRrhythmogenic substrate Of Lasting-A trial Fibrillation (CONTROL-AF) Study - CONTROL-AF
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 21years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients whose atrial fibrillation was restored after only pulmonay veins isolation Patients who received ablation procedure or MAZE procedure for for atrial fibrillation before enrollment
研究者
相似试验
招募中
4 期
The Randomized Controlled Trial Evaluating Utility of Catheter Ablation Us ing New Strategy Targeting Arrhythmogenic Substrate in Atrial Fibrillation PatientsAtrial fibrillationJPRN-jRCT1052210010Shizuta Sastoshi80
暂停
3 期
Non-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to its deferred administration.
FEFACRIGOU2024-515547-34-00Centre Hospitalier Universitaire Rouen128
进行中（未招募）
1 期
on-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to its deferred administration. FEFACRIGOThe goutMedDRA version: 21.0Level: LLTClassification code: 10003435Term: Articular gout Class: 10027433CTIS2024-515547-34-00Centre Hospitalier Universitaire Rouen128
招募中
不适用
Development of novel treatment strategy to prevent progression of arteriosclerosis in dialysis patientsend stage renal diseaseJPRN-UMIN000020384second department of internal medicine, Kansai Medical University Hirakata hospital100
进行中（未招募）
1 期
Evaluation d’une nouvelle stratégie thérapeutique chez des patients à fort risque évolutif, à la phase initiale de la sclérose en plaques : traitement séquentiel par mitoxantrone (Elsep 10mg/m² par mois pendant 6 mois) puis interféron bêta-1a (Rebif 44µg 3 fois par semaine) versus interféron bêta-1a seul. - 2MS1Sclérose en plaquesEUCTR2004-001601-10-FRCHRU Rennes266